BOLD Innovation That Matters: Episode 4


Dear colleagues and friends,


We recognize the pivotal roles breakthrough science plays in transforming patients' lives, and the challenges in bridging the gap between science and development. It is our pleasure to invite you to an exclusive global online event dedicated to unraveling this very conundrum: Translating Science into Meaningful Therapies.


WuXi AppTec is committed to fostering innovation as a dedicated enabler, a trusted partner, and an active contributor to advancing breakthroughs for patients. By working together, we can think boldly and act boldly in addressing global health challenges!




8:00 Welcome

Hui Cai, Program Chair and Vice President, WuXi AppTec


8:05 From Bench to Bedside: Delivery on the Promise of Breakthrough Science

Paulo Fontoura, Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development, Roche

Edward Hu, Vice Chairman, WuXi AppTec


8:25 Spotlight Track I: Leading the Next Generation Therapies

Jim Broderick, CEO & Founder, Palleon Pharmaceuticals

Dina Burkitbayeva, CEO & Co-Founder, Freedom Biosciences

Tianjing (TJ) Deng, CEO & Co-Founder, Pyrotech Therapeutics

Vishal Doshi, Chairman & CEO, AUM Biosciences

Zachary Hornby, CEO, President & Director, Boundless Bio

Danuta Jeziorska, CEO & Co-Founder, Nucleome Therapeutics

Philip Kantoff, Co-Founder & CEO, Convergent Therapeutics


8:45 Small Molecules. Big Opportunities.

Michelle Arkin, Professor & Chair, Pharmaceutical Chemistry, UCSF

Eric Fischer, Director, Chemical Biology Program, Dana-Farber Cancer Institute; Professor, Harvard Medical School

Kevan Shokat, Professor, Department of Cellular and Molecular Pharmacology, UCSF, Department of Chemistry, UC Berkeley; Investigator, HHMI


9:15 Spotlight Track II: Leading the Next Generation Therapies

Paul Lammers, CEO, Triumvira Immunologics

Robert Li, Founder & CEO, LTZ Therapeutics

Roy Maute, Co-Founder & CSO, Pheast Therapeutics

Giuseppe Mazza, CEO & Co-Founder, Engitix; Honorary Associate Professor, UCL

Jon Moore, Co-Founder & CEO, Epitopea

Joseph Nabhan, CSO, Vesigen Therapeutics

Taku Nakahara, Founder & CEO, Metagen Therapeutics

Lars Nieba, CEO, Engimmune Therapeutics

9:35 Perspectives on Translating Genetic Medicines

Catriona Jamieson, Professor of Medicine and Koman Family Presidential Endowed Chair in Cancer Research, UC San Diego; Founder, Aspera Biomedicines

David Schaffer, Professor, Chemical & Biomolecular Engineering, Bioengineering, and Molecular & Cell Biology, Neuroscience, UC Berkeley


9:55 Spotlight Track III: Leading the Next Generation Therapies

Daisy Robinton, Co-Founder, CEO and Board Director, Oviva Therapeutics

Catherine Sabatos-Peyton, CEO, Larkspur Biosciences

Avencia Sánchez-Mejías, Co-Founder & CEO, Integra Therapeutics

Ishita Shah, CEO & Co-Founder, Matrubials

Nicholas Siciliano, CEO & Co-Founder, Vittoria Biotherapeutics

Uttam Surana, Adjunct Professor, Department of Pharmacology, National University of Singapore; Co-Founder, Aldropika Therapeutics

Leslie Williams, Co-Founder, President & CEO, hC Bioscience


10:15 Closing Remarks

Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec


Please click here for the speaker bios.